Quick answer
Two patients can have normal LDL cholesterol and still develop diabetes, heart disease and stroke together — a cluster called cardiometabolic multimorbidity. A team at Hubei Provincial Hospital of TCM's health management centre combined LDL cholesterol with the Chinese visceral adiposity index into a single score, the Visceral Lipoprotein Risk (VLR) index, and tested it in 8,813 adults. High VLR was associated with roughly three times the risk of cardiometabolic multimorbidity [1][2].
Key takeaways
- Data came from a national prospective cohort (CHARLS) of middle-aged and older Chinese adults [1][3].
- 8,813 participants with cardiometabolic multimorbidity were analysed [1][2].
- High VLR was associated with an HR of 3.12 (95% CI 2.39–4.08) for incident cardiometabolic multimorbidity [3].
- Discrimination was good, with an AUC of 0.78 [2].
- The paper appeared in Cardiovascular Diabetology (IF 10.6), with Dong Jin and Yang Fan as corresponding authors [1].
Why combine the two measures
LDL cholesterol is the standard lipid target, but it misses the metabolic risk carried by visceral fat — the fat around organs rather than under the skin. The Chinese visceral adiposity index (CVAI) estimates that compartment from waist circumference, BMI, triglycerides and age, and has been linked to diabetes and cardiovascular events in Chinese populations [2][3].
Combining the two capture different mechanisms: LDL drives atherosclerosis, while visceral fat drives insulin resistance, inflammation and dyslipidaemia. A patient can be normal on one axis and abnormal on the other, which is why the composite performed better than either alone [1][2].
What the study found
Across the cohort, higher VLR scores tracked higher incidence of multimorbidity, with the top category showing about a threefold risk after adjustment. The AUC of 0.78 indicates moderate-to-good discrimination — useful for stratifying a population, not for diagnosing an individual. The authors position it as a screening and triage tool that could be calculated from routine data [2][3].
This is observational cohort work: it shows association and discrimination, not that lowering VLR prevents disease. CHARLS is a well-known national cohort, but self-reported diagnoses and single-timepoint measures limit precision. External validation in other populations and a prospective impact study would be needed before clinical adoption [1][2].
The condition in context: cardiometabolic multimorbidity
Having two or more of diabetes, heart disease and stroke is common in older adults and worse than the sum of its parts.
| Region | What the data shows | Source |
|---|---|---|
| China | About 75% of cancer patients have at least one other chronic condition, and multimorbidity is rising with ageing [4]. | Hubei Cancer Hospital [4] |
| Risk factors | LDL cholesterol and visceral adiposity are each established, and their combination adds information [1][2]. | Cardiovascular Diabetology [1][2] |
| Screening gap | Normal lipid panels can mask visceral-fat-driven risk, which the composite index is designed to expose [1][5]. | Jingchu Network [1] |
Because multimorbidity changes treatment priorities and prognosis, identifying it earlier allows earlier prevention rather than later polypharmacy [1][4].
Why it matters
| Potential | What the report suggests | Source |
|---|---|---|
| Practicality | Both inputs come from routine measurements [2]. | [2] |
| Stratification | AUC 0.78 supports population-level risk tiers [3]. | [3] |
| Caution | Observational; no evidence that intervening on VLR changes outcomes [1]. | [1] |
Availability and limits
- This is an editorial summary of the publication and hospital reports, not a clinical tool [1][2].
- The index is not validated for individual diagnosis [3].
- CHARLS relies partly on self-reported diagnoses [2].
- Cut-offs derived in one population may not transfer [1][5].
- Whether using VLR improves outcomes has not been tested [2].
What to ask before booking
| Question | Why it matters |
|---|---|
| What is my waist circumference and visceral fat estimate? | Visceral adiposity adds risk beyond LDL [2]. |
| Do I already have two or more cardiometabolic conditions? | Multimorbidity changes treatment targets [4]. |
| Which department handles foreign patients, and in what language? | The hospital is a working hospital we do not book; confirm international-department coordination and language support. |
| What intervention follows a high score? | Screening is only useful with a management plan [1]. |
Questions patients ask
What is the VLR index?
A composite of LDL cholesterol and the Chinese visceral adiposity index, designed to stratify cardiometabolic multimorbidity risk in middle-aged and older adults [1][2].
What did the study find?
In 8,813 adults, high VLR carried about three times the risk of cardiometabolic multimorbidity (HR 3.12) with an AUC of 0.78 [2][3].
Where was it published?
Cardiovascular Diabetology (IF 10.6), with Dong Jin and Yang Fan as corresponding authors [1].
Can it be used clinically now?
It is a research risk-stratification tool; external validation and impact studies are needed [2].
Is this relevant to international patients?
It is useful context for China's preventive cardiometabolic care. The hospital is a working hospital we do not book — contact its international department directly [1].